Trial intelligence / Profile preview

Bioavailability comparison of etoricoxib 120 mg tablets from Spain vs USA manufacturing sites

NL-OMON37397Active, not recruiting

Sponsor
Merck & Co.
Start
Feb 2012
Modality
Small Molecules
Countries
1
01

Overview

Randomised, open-label trial of etoricoxib in osteoarthritis (OA) and rheumatism (2 arms), sponsored by Merck & Co. Primary endpoint: Relative bioavailability of etoricoxib 120 mg tablets manufactured at Frosst Iberica, Spain and Elkton, VA, USA. Started Feb 2012; status: active, not recruiting.

02

Drugs

etoricoxib
03

Conditions

osteoarthritis (OA)rheumatism

Beyond the preview

Go deeper on NL-OMON37397.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON37397.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call